Clinical Trial Update: Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) [Phase 3]

View source ↗

Summary

DAISY is a Phase 3 trial evaluating the effectiveness of anifrolumab in systemic sclerosis; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• Anifrolumab (anifrolumab)

Snippet

Sponsor: AstraZeneca | Conditions: Systemic Sclerosis, Scleroderma | Phase 3 | Status: ACTIVE_NOT_RECRUITING